Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29920980 | 0.85 | MAPT (0.39) | MAPTKMT2AALDH1A1 | |
| SCHEMBL23834830 | 0.85 | MAPT (0.39) | MAPTKMT2AALDH1A1 | |
| SCHEMBL23495404 | 0.83 | RAPGEF4 (0.41) | RAPGEF4RIPK1ALDH1A1 | |
| SCHEMBL601770 | 0.80 | DGAT1 (0.31) | TAAR1 | |
| SCHEMBL8135181 | 0.79 | RIPK1 (0.30) | RIPK1 | |
| SCHEMBL1139983 | 0.78 | TSHR (0.35) | TAAR1ALDH1A1 | |
| SCHEMBL23495368 | 0.78 | TAAR1 (0.30) | TAAR1 | |
| SCHEMBL6026539 | 0.78 | RAPGEF4 (0.35) | RAPGEF4TAAR1 | |
| SCHEMBL31413122 | 0.78 | TRPV4 (0.35) | — | |
| SCHEMBL2091126 | 0.75 | GPR84 (0.38) | RAPGEF4RIPK1CES2CES1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132136-A1 | Pyrazolo[5,1-f][1,2,4]triazin-4-ones as inhibitors of NOX4 | BOEHRINGER INGELHEIM INT GMBH (DE) | 2026-05-14 | — | — | US | disclosed |
| CN-122010947-A | Antagonists of adenosine A2a receptors | 阿道尔克斯治疗有限公司 | 2026-05-12 | — | — | CN | disclosed |
| WO-2026046899-A1 | PYRAZOLO[5,1-f][1,2,4]TRIAZIN-4-ONES AS INHIBITORS OF NOX4 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-03-05 | — | — | WO | disclosed |
| US-20260007672-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2026-01-08 | — | — | US | disclosed |
| EP-4673447-A1 | [1,3]THIAZOLO[4,5-D]-PYRIMIDIN-7-ONES AS INHIBITORS OF NOX4 | Boehringer Ingelheim International GmbH (DE) | 2026-01-07 | — | — | EP | disclosed |
| US-12491185-B2 | Inhibitors of mPTP | NRG THERAPEUTICS LTD (GB) | 2025-12-09 | — | — | US | disclosed |
| EP-4652162-A1 | INHIBITORS OF MPTP | NRG Therapeutics LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-20250177397-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| WO-2025096453-A1 | COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-3689879-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2025-02-12 | — | — | EP | disclosed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1999010331-A1 | ARYLPYRIDAZINONES AS PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| US-5594016-A | ANTIDIABETIC AGENTS | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-01-14 | — | — | US | disclosed |
| EP-0604983-B1 | Naphthalene derivatives | MITSUBISHI CHEM CORP (JP) | 1996-11-20 | — | — | EP | disclosed |
| US-5409943-A | [(alkoxy)pyridinyl]amine compounds which are useful in the treatment of gastrointestinal disorders | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1995-04-25 | — | — | US | disclosed |
| EP-0625143-A1 | PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1994-11-23 | — | — | EP | disclosed |
| EP-0604983-A1 | Naphthalene derivatives | Mitsubishi Chemical Corporation (JP) | 1994-07-06 | — | — | EP | disclosed |
| WO-1993015055-A1 | PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491185-B2 | Inhibitors of mPTP | PARK7, PINK1, SNCA | RAPGEF4 813/4885RIPK1 1054/4885CES2 1079/4885 |
| US-20260132136-A1 | Pyrazolo[5,1-f][1,2,4]triazin-4-ones as inhibitors of NOX4 | NOX4, NOX1, NOX3 | RAPGEF4 670/4885RIPK1 3960/4885CES2 1019/4885 |
| US-20250177397-A1 | INHIBITORS OF MPTP | PARK7, PINK1, SNCA | RAPGEF4 813/4885RIPK1 1054/4885CES2 1079/4885 |
| US-20260007672-A1 | INHIBITORS OF MPTP | PARK7, SNCA, CYC1 | RAPGEF4 1102/4885RIPK1 1744/4885CES2 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.